| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 03/01/2007 | CA2619581A1 8-substituted benzoazepines as toll-like receptor modulators |
| 03/01/2007 | CA2619518A1 Isotopically substituted benzimidazole derivatives |
| 03/01/2007 | CA2619441A1 Acetylcysteine composition and uses therefor |
| 03/01/2007 | CA2619396A1 Solid pharmaceutical composition comprising 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine and a ph modifier |
| 03/01/2007 | CA2619366A1 Bis-aryl urea compounds for the treatment of protein kinase-mediated diseases |
| 03/01/2007 | CA2619365A1 Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| 03/01/2007 | CA2619362A1 Fused tricyclic mglur1 antagonists as therapeutic agents |
| 03/01/2007 | CA2619111A1 Fused aminopiperidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes |
| 03/01/2007 | CA2619038A1 (indol-3-yl)-heterocycle derivatives as agonists of the cannabinoid cb1 receptor |
| 03/01/2007 | CA2619037A1 Bicyclic heterocycles medicaments comprising said compounds use and method for production thereof |
| 03/01/2007 | CA2619035A1 Pharmaceutical compositions |
| 03/01/2007 | CA2618770A1 Hif inhibitors |
| 03/01/2007 | CA2618700A1 Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof |
| 03/01/2007 | CA2618482A1 Dual variable domain immunoglobin and uses thereof |
| 03/01/2007 | CA2618479A1 Pyrazine derivatives and use as pi3k inhibitors |
| 03/01/2007 | CA2618087A1 Bridged n-bicyclic sulfonamido inhibitors of gamma secretase |
| 03/01/2007 | CA2617980A1 Combination of a hypnotic agent and substituted bis aryl and heteroaryl compound and therapeutic application thereof |
| 03/01/2007 | CA2617975A1 Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| 03/01/2007 | CA2617519A1 Agent for treating atrial fibrillation |
| 03/01/2007 | CA2617510A1 Use of iron (iii) complex compounds for the preparation of a medicament for oral treatment of iron deficiency states in patients with chronic inflammatory bowel disease |
| 03/01/2007 | CA2612161A1 Use of non-steroidal progesterone receptor modulators |
| 03/01/2007 | CA2611736A1 Benzo[b]furane and benzo[b]thiophene derivatives |
| 03/01/2007 | CA2610475A1 Derivative prodrugs of ethinyl estradiol |
| 03/01/2007 | CA2609948A1 Vasoactive kit and composition and uses thereof |
| 03/01/2007 | CA2606879A1 Process of making geminal bisphosphonic acids and pharmaceutically acceptable salts and/or hydrates thereof |
| 03/01/2007 | CA2602969A1 Sulfonamides |
| 03/01/2007 | CA2556343A1 Synthetic nutritional formulations |
| 02/28/2007 | EP1757944A1 A method of determining the initial dose of vitamin D compounds |
| 02/28/2007 | EP1757937A2 Antagonists of HMG1 for treating inflammatory conditions |
| 02/28/2007 | EP1757689A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 02/28/2007 | EP1757621A2 Compositions and methods for the treatment and diagnosis of immune disorders |
| 02/28/2007 | EP1757618A2 Angiogenesis-associated proteins, and nucleic acids encoding the same |
| 02/28/2007 | EP1757617A1 Ret Ligand (RetL) for stimulating neural and renal growth |
| 02/28/2007 | EP1757610A1 Condensed pyrimidine derivative and xanthine oxidase inhibitor |
| 02/28/2007 | EP1757609A1 Novel water-soluble prodrug |
| 02/28/2007 | EP1757608A1 New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments |
| 02/28/2007 | EP1757607A1 N5-substituted benzo¬2,3|azepino¬4,5-b|indol-6-ones for treating tropical diseases |
| 02/28/2007 | EP1757606A1 Xanthinderivatives, preparation thereof and their use as medical agents |
| 02/28/2007 | EP1757605A1 Cyclic amine compound |
| 02/28/2007 | EP1757604A1 Process for producing solifenacin or its salt |
| 02/28/2007 | EP1757603A1 Therapeutic agent for keratoconjunctiva disorder |
| 02/28/2007 | EP1757602A1 Vla-4 inhibitor |
| 02/28/2007 | EP1757601A1 Quinoline derivatives and their use in glaucoma and myopia |
| 02/28/2007 | EP1757600A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 02/28/2007 | EP1757599A1 Indole derivatives having piperidine rings |
| 02/28/2007 | EP1757598A1 Substituted pyrrolidine derivative |
| 02/28/2007 | EP1757596A1 Tyrosine derivatives substituted by n-phenylacryloyl as agonists of hppar alpha and hppar gama |
| 02/28/2007 | EP1757594A1 Quinazoline derivative |
| 02/28/2007 | EP1757593A1 Therapeutic agent for nonviral hepatitis |
| 02/28/2007 | EP1757592A1 Novel 3-phenyltetrahydrocinnolin-5-ol derivative and medicinal use thereof |
| 02/28/2007 | EP1757591A1 Cinnamide compound |
| 02/28/2007 | EP1757590A1 Piperazinylalkylpyrazole derivatives useful as selective T-type calcium channel blockers and preparation method thereof |
| 02/28/2007 | EP1757589A1 Amorphous phase of a substituted pyrazoline, its preparation and use as medicament |
| 02/28/2007 | EP1757588A1 Polymorph of N-Piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4,5-dihydro-1H-pyrazole-3-carboxamide and its use as a cannabinoid receptor modulator |
| 02/28/2007 | EP1757587A1 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 02/28/2007 | EP1757586A1 Polysbustituirte 1,1-pyridinylaminocyclopropanamin derivate, verfahren zu deren herstellung und diese enthaltende pharmatuetische zusammensetzung |
| 02/28/2007 | EP1757584A1 Heterocyclic substituted amides, their production and their use |
| 02/28/2007 | EP1757582A1 Arylalkylamines and process for production thereof |
| 02/28/2007 | EP1757362A1 Adsorbent and process for producing the same |
| 02/28/2007 | EP1757324A2 Agent for preventing, improving or treating hypertension |
| 02/28/2007 | EP1757306A1 Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| 02/28/2007 | EP1757299A1 Complexes of iron III for treating iron deficiencies in patients with inflammatory bowel disease |
| 02/28/2007 | EP1757298A1 Method of potentiating bioloigcal actions of living organism being in contact with aqueous environment and/or enlarging area suitable for biological actions |
| 02/28/2007 | EP1757297A1 Composition for inhibiting the onset of arteriosclerosis and inhibition method |
| 02/28/2007 | EP1757296A1 Method of controlling the proliferation of vascular endothelial cells and inhibiting lumen formation |
| 02/28/2007 | EP1757295A1 Peripheral-Type benzodiazepine receptor: a tool for detection, diagnosis, prognosis, and treatment of cancer |
| 02/28/2007 | EP1757294A1 Orally-administered aqueous risperidone solution |
| 02/28/2007 | EP1757293A1 Bh4-responsive hyperphenylalaninemia remedies |
| 02/28/2007 | EP1757292A1 Method of treating ocd and tic disorders |
| 02/28/2007 | EP1757291A2 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| 02/28/2007 | EP1757290A1 Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
| 02/28/2007 | EP1757289A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 02/28/2007 | EP1757287A1 Pharmaceutical composition for prevention or treatment of lipid metabolism disorder |
| 02/28/2007 | EP1757286A1 The application of l-n-butylphthlide in preventing and treating dementia |
| 02/28/2007 | EP1757285A1 Preventive and/or therapeutic agent for chronic sinusitis |
| 02/28/2007 | EP1757284A1 Use of N-(dibenz(b,f)oxepin-10ylmethyl)-N-methyl-N-prop-2-ynylamine (omigapil) for the prophylaxis and/or treatment of muscular dystrophy |
| 02/28/2007 | EP1757283A1 Antitumor effect fortifier, antitumor agent and method of therapy for cancer |
| 02/28/2007 | EP1757282A1 The use of kauranes compounds in the manufacture of medicament |
| 02/28/2007 | EP1757281A2 Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist |
| 02/28/2007 | EP1757280A1 Transdermal patch for administering sufentanyl |
| 02/28/2007 | EP1757279A1 Dissolvable film |
| 02/28/2007 | EP1757277A1 Oral preparations and process for production thereof |
| 02/28/2007 | EP1757275A1 Seamless capsule containing water-soluble active ingredient |
| 02/28/2007 | EP1757274A1 Effervescent composition against cold symptoms |
| 02/28/2007 | EP1757273A1 Preparation for oral administration |
| 02/28/2007 | EP1757272A2 Drug-release system and its use |
| 02/28/2007 | EP1756310A2 Polymorphisms in abcb1 associated with a lack of clinical response to medicaments |
| 02/28/2007 | EP1756288A2 Adeno-associated virus vectors with intravector heterologous terminal palindromic sequences |
| 02/28/2007 | EP1756270A2 Diagnosis and treatment of myeloid and lymphoid cell cancers |
| 02/28/2007 | EP1756140A1 Selective separation or extraction of steroidal glycosides by supercritical fluid extraction using carbon dioxide |
| 02/28/2007 | EP1756139A2 Antiangiogenic agents |
| 02/28/2007 | EP1756135A1 Ester linked macrolides useful for the treatment of microbial infections |
| 02/28/2007 | EP1756134A1 Carbamate linked macrolides useful for the treatment of microbial infections |
| 02/28/2007 | EP1756133A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1 |
| 02/28/2007 | EP1756132A1 Process for preparing an iron saccharose complex |
| 02/28/2007 | EP1756120A1 Purine derivative |
| 02/28/2007 | EP1756118A1 Tetrahydropyridothiophenes for use in the treatment of cancer |
| 02/28/2007 | EP1756116A1 Polymorphic forms of methyl(+)-(s)-alpha-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4h) acetate hydrobromide, clopidrogel hydrobromide |
| 02/28/2007 | EP1756114A2 Hiv integrase inhibitors |
| 02/28/2007 | EP1756113A1 Compounds containing a n-heteroaryl moiety linked to fused ring moieties for the inhibition of nad(p)h oxidases and platelet activation |